Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sar9, Met (O2)11–Substance P is a synthetic peptide analog of the neuropeptide Substance P. It features two key modifications: sarcosine at position 9 and methionine sulfoxide at position 11. This compound acts as a potent and selective agonist of the neurokinin 1 receptor (NK1R), also known as the tachykinin NK1 receptor. The NK1 receptor is widely distributed in both central and peripheral nervous systems and mediates many physiological responses to Substance P, including pain transmission, inflammation, and smooth muscle contraction. As an investigational tool compound rather than a marketed pharmaceutical product, it is primarily used in research settings to study NK1 receptor function[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sar9, Met (O2)11-Substance P.